Clinical Trial Update: A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study of CP-4055 in platinum-resistant ovarian cancer has completed, as reported by sponsor Clavis Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CP-4055

Snippet

Sponsor: Clavis Pharma | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED